AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04583306 — intervention group
Intervention type: OTHER
Intervention: Raman analysis of saliva, characterization of the Raman database and building of the classification model
Description: Saliva will be collected, processed and analysed through Raman spectroscopy. Data acquired will be normalized and treated for the creation of the classification model.
Study NCT01495663 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: I-131-CLR1404
Description: Description:~* Dosimetry: IV, 5 mCi, single dose, 6-day duration~* Therapy: IV, starting dose level of 12.5 mCi/m2, single dose, 56-day duration with follow up to one year
Study NCT01197807 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bulb Suctioning
Description: Bulb suctioning of the mouth then the nose immediately following delivery
Study NCT01197807 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wiping
Description: Gentle wiping of mouth then nose with a soft cloth immediately following delivery
Study NCT03197090 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zenicor ECG
Description: Participants will place their thumbs on the device twice daily and whenever they notice palpitations.
Study NCT02731885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464 Single dose
Description: Two-periods, subjects received a single dose of 50mg of ABX464 in fed and fasted condition, separated by a wash-out period of at least 45 days.
Study NCT02731885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464 Repeated dose
Description: Subjects received 50mg of ABX464 every 3 days during 10 days in fasted or fed condition.
Study NCT00281424 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pedometer
Description: gave pedometer and info
Study NCT02958397 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD33-CAR-transduced T cells
Description: The first 3 enrolled patients will receive autologous-derived CD33-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity,the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
Study NCT02635152 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpretation Bias Modification
Description: Eight 10-25 minute sessions of interpretation modification to reduce negative interpretation biases related to appearance.
Study NCT02635152 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Muscle Relaxation
Description: Eight 15-minute sessions of progressive muscle relaxation (PMR).
Study NCT00839371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: i.v. propofol titration until adequate depth of sedation
Study NCT00434122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix mid-luteal, 2.5 mg
Description: Degarelix 2.5 mg will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak and on Stimulation Day 6. Placebo will be injected SC on Stimulation Day 1.
Study NCT00434122 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak. Degarelix 2.5 mg will be injected SC on Stimulation Day 1 and Stimulation Day 6.~or Placebo will be injected SC 7 days after LH peak and on Stimulation Day 1. Ganirelix 0.25 mg will be injected SC daily from Stimulation Day 6 until the last stimulation day.
Study NCT05341674 — intervention group
Intervention type: OTHER
Intervention: the stumps of all patients were scanned with the Artec Eva Lite brand 3D scanner.
Description: the stumps of all patients were scanned with the Artec Eva Lite brand 3D scanner.
Study NCT01575405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rectal formulation (RF) of tenofovir 1% gel
Description: The RF is a translucent colorless viscous gel formulation containing 1% (w/w) of tenofovir (PMPA) formulated in purified water with EDTA, glycerin, methylparaben, propylparaben, carbopol, sodium carboxy methyl cellulose, and pH adjusted to 7. The RF is close to isoosmolar with an osmolality of 479 mOsmol/kg. Seven doses of this formulation will be used.
Study NCT01575405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal formulations (original VF and reduced vaginal glycerin formulation RGVF) of tenofovir 1% gel
Description: The original VF is a transparent, viscous gel formulation containing 1% (weight/weight) of tenofovir (PMPA, 9-\[(R)-2-(phosphonomethoxy) propyl\]adenine monohydrate), formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben, hydroxyethylcellulose, and pH adjusted to 4-5. One dose of this formulation will be used, with 6 doses of the HEC placebo gel preceding it to balance out this study stage. The reduced glycerin formulation (RGVF) is a modification of the original VF - it has lower glycerin content than the VF and a significantly reduced osmolality (836 or 846 versus 3111 mOsmol/kg). Lowering the glycerin content lowered the viscosity, so the HEC concentration was increased by 10% (a change considered to be insignificant). The amount of parabens was increased by 10% each to improve the antimicrobial effectiveness. The RGVF formulation has since been modified to increase the viscosity. Seven doses of RGVF will be used in this study.
Study NCT01575405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Universal HEC Placebo Gel Formulation
Description: The Universal HEC Placebo Gel contains hydroxyethylcellulose as the gelling agent, purified water, sodium chloride, sorbic acid and sodium hydroxide. The gel is isotonic and formulated at a pH of 4.4 to avoid disrupting the normal vaginal pH and has minimal buffering capacity to avoid the inactivation of sexually transmitted pathogens. Hydroxyethylcellulose is used to approximate the viscosity of microbicide gel candidates. Each pre-filled applicator will deliver approximately 4 mL of HEC placebo gel. Six doses of this gel will be used to balance out the VF stage of the study.
Study NCT00536042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: addition of 150 mg to 250 mg po bid to standard asthma care regiment
Study NCT00839371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: i.v. midazolam titration until adequate depth of sedation
Study NCT01091831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be given orally at the dose of 300 mg/m2 on days 1, 8, 15 for 6 cycles every 28 days
Study NCT01091831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide will be given orally at the dose of 25 mg/d for 21 days followed by a 7 days rest period (day 22 to 28)for 6 cycles every 28 days
Study NCT01091831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone will be given orally at the dose of 40 mg on days 1, 8, 15, 22 for 6 cycles every 28 days
Study NCT01091831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Melphalan will be given iv at the dose of 200 mg/m2 for 1 day followed by stem cell support. The second MEL200 was performed 120 days after the first if ≤ PR was achieved after the 1st MEL200.
Study NCT03158025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo lemborexant
Description: Placebo 1 x 10 mg, 2 x 10 mg, or 3 x 10 mg lemborexant tablets will be administered orally.
Study NCT01113398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 102
Description: AMG 102 will be administered as a continuous intravenous infusion by an infusion pump at 20 mg/kg every 2 weeks over 60 or 30 minutes.
Study NCT01113398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Avastin will be administered as a continuous intravenous infusion at 10 mg/kg every 2 weeks (6-week study cycle) over 60 or 30 minutes. Avastin will be given prior to AMG 102.
Study NCT02620462 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable sensor-based exercise training
Description: The device provides real-time visual feedback of joint movement during balance exercise
Study NCT03787654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin
Description: Subjects take solifenacin 5-10mg per day for a succession of 36 weeks. The dose change is decided by doctors under a comprehensive consideration of side effects and Patient Global Symptom Control (PGSC), which is applied to evaluate the effectiveness of Solifenacin at the 4th, 8th, 12th and 24th week.The medicine can be discontinued at any time if the adverse effect is rather severe.
Study NCT00508521 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation
Description: commercially available surface electrical stimulator
Study NCT00508521 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: Standard care as ordered by their physician and covered by their insurance company.
Study NCT01029431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AirQ Intubating Laryngeal Airway
Description: After induction of anaesthesia in each child, either a PLMA or an Air-Q® ILA of the weight-appropriate size will be inserted \& the evaluation described below will be conducted. The first LMA will then be removed \& the other device inserted \& assessed. The order in which the LMA devices are inserted will be determined using block randomisation, with random block sizes, after recruitment \& before induction of anesthesia. The anesthesiologist will insert the LMAs using the manufacturer's recommended technique, \& inflate the cuff to the manufacturer's recommended intracuff pressure of 60 cm H2O. Intracuff pressure will be measured with a digital pressure cuff monitor.
Study NCT03107403 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: web form
Description: The scale assessing the bereavement process is the one reported in Teissier 2010
Study NCT01740063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAS181-F02 formulation
Study NCT01740063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAS181-F04 formulation
Study NCT01740063 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03941912 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Erchonia EVRL
Description: Single treatment with the Erchonia EVRL to the neck and shoulders. The treatment applies 635 nanometers (nm) red diode light and 405 nm violet diode light simultaneously.
Study NCT03444649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat orally two times daily (BID) for two cycles (28 days each) in combination with standard induction chemotherapy (Idarubicin and Cytarabine)
Study NCT03444649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Standard chemotherapy d1-d3 cycle 1
Study NCT03444649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Standard chemotherapy d1-d7 cycle 1 and 2
Study NCT03444649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Standard chemotherapy d1-3 cycle 2
Study NCT01169311 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemorrhoidopexy
Study NCT03130439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib (LY2835219) has been shown in vitro to be a selective ATP-competitive inhibitor of CDK4 and CDK6 kinase activity that prevents the phosphorylation and subsequent inactivation of the Rb tumor suppressor protein, thereby inducing G1 cell cycle arrest and inhibition of cell proliferation.
Study NCT02418013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fresh cord blood(experimental group A)
Description: 1. Cord blood is administered through intravenous at CHA clinical trail institute.~2. Chlorpheniramine maleate at the concentration of 0.6ml/10kg is administered prior to the treatment.
Study NCT02418013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frozen cord blood(experimental group B)
Description: 1. Cord blood is administered through intravenous at CHA clinical trail institute.~2. Chlorpheniramine maleate at the concentration of 0.6ml/10kg is administered
Study NCT02418013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frozen plasma(experimental group C)
Description: 1. Cord blood is administered through intravenous at CHA clinical trail institute.~2. Chlorpheniramine maleate at the concentration of 0.6ml/10kg is administered
Study NCT02418013 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: A placebo agent is administered through intravenous at CHA clinical trail institute.~It should be certain that when administered, participants are not aware of which treatments are preformed.
Study NCT02383108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG +DRV/r
Description: NRTI-sparing regimen: Once daily integrase inhibitor (INSTI) + darunavir/ritonavir (DRV/r)
Study NCT02383108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOC
Description: Standard of care (continuing triple anti-retroviral therapy including 2 NRTIs + boosted PI/NNRTI)
Study NCT00971711 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: The subjects will be randomized into either a 4 week or 8 week treatment period with the probiotic. The treatment will be open label. They will take 2 packets once daily.
Study NCT01178632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Passiflora
Description: 01 tablet Passiflora p.o., b.i.d.
Study NCT01178632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valeriana officinalis
Description: Active Comparator group will receive 01 tablet of Valeriana officinalis, p.o., b.i.d.
Study NCT04889131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Program Immediately
Description: free 12 week yoga program, twice a week for 75 minutes each
Study NCT04889131 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wait-Listed Control
Description: assigned to take the Yoga Program in 12-weeks
Study NCT04889131 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Activity Monitor
Description: Garmin VivoSmart activity monitor throughout study
Study NCT04889131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity Monitor
Description: Garmin VivoSmart activity monitor throughout study
Study NCT04045886 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Educational Modules (Videos)
Description: 5 educational online modules (videos) about DNR/goals of care discussions that the participant will watch as part of the intervention. This is the only intervention.
Study NCT04045886 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Educational Modules (Videos)
Description: 5 educational online modules (videos) about DNR/goals of care discussions that the participant will watch as part of the intervention. This is the only intervention.
Study NCT03814252 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI-TULSA
Description: The technology is developed to ablate targeted prostate tissue through transurethrally inserted probe that transmit ultrasound energy under MRI guidance and control. The therapeutic endpoint of this method is thermal coagulation of prostate tissue.~TULSA-PRO (Profound Medical Inc, Toronto, Canada): PAD-105, integrated into a 3 Tesla MR-system (Ingenia 3.0 Tesla, Philips Healthcare, Best, Netherlands)
Study NCT00415090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: Switch one of ARV drugs to Nevirapine
Study NCT01468064 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous BMSCs transplantation
Description: The first transplantation: 2.5 million cells per kg autologous BMSCs suspended in 100 ml saline plus 5% autologous serum are infused intravenously approximately 4 weeks after bone marrow aspiration.~The second transplantation: the same amount of cells are again transplanted approximately 1 weeks after initial boosting.
Study NCT01468064 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous EPCs transplantation
Description: The first transplantation: 2.5 million cells per kg autologous EPCs suspended in 100 ml saline plus 5% autologous serum are infused intravenously approximately 4 weeks after bone marrow aspiration.~The second transplantation: the same amount of cells are again transplanted approximately 1 weeks after initial boosting.
Study NCT01468064 — intervention group
Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: IV infusion of placebo
Description: IV infusion of saline plus 5% autologous serum.
Study NCT02415556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Human Insulin
Description: Regular human insulin 40 IU daily over 24 weeks
Study NCT02415556 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intranasal sterile saline 40 IU daily over 24 weeks
Study NCT02390076 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Left Low Level Light Therapy
Description: Administration of left LLLT consists of applying light of a specific wavelength (1064 nanometers) using a laser diode, the CG-5000 high density laser (Cell Gen Therapeutics, LLC). Left LLLT will target the left forehead. The diameter parameters of stimulation are the same that showed psychologically beneficial effects in Schiffer et al. (2009). At the power level described, the energy emitted by the CG-5000 at this setting is one quarter of the skin MPE (0.250 W/cm2), exposure to it is not deemed harmful to tissue, and it causes no detectable physical damage and negligible heat.
Study NCT02390076 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention bias modification
Description: The task will consist of a modified dot-probe paradigm. A pair of stimuli depicting a negative word and a neutral word will be presented, randomly located to the right and left side of the computer screen. The words will be presented for 1000 ms. The words will then disappear and a dot-probe will appear in the center of the screen location of one of the words (i.e., O or Q). This probe will appear on the screen until the participant presses one of two response buttons to indicate the identity of the probe. The presentation of the probe will be staggered to maximize attention for the neutral stimulus. Latency and accuracy of the button press responses are recorded by the computer.
Study NCT02390076 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Attention bias modification
Description: The task will consist of a modified dot-probe paradigm. A pair of stimuli depicting a negative word and a neutral word will be presented, randomly located to the right and left side of the computer screen. The words will be presented for 1000 ms. The words will then disappear and a dot-probe will appear in the center of the screen location of one of the words (i.e., O or Q). This probe will appear on the screen until the participant presses one of two response buttons to indicate the identity of the probe. The presentation of the probe will be staggered to maximize attention for the neutral stimulus. Latency and accuracy of the button press responses are recorded by the computer.
Study NCT02390076 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Right Low Level Light Therapy
Description: Administration of right LLLT consists of applying light of a specific wavelength (1064 nanometers) using a laser diode, the CG-5000 high density laser (Cell Gen Therapeutics, LLC). Right LLLT will target the right forehead. The diameter parameters of stimulation are the same that showed psychologically beneficial effects in Schiffer et al. (2009). At the power level described, the energy emitted by the CG-5000 at this setting is one quarter of the skin MPE (0.250 W/cm2), exposure to it is not deemed harmful to tissue, and it causes no detectable physical damage and negligible heat.
Study NCT02390076 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Low Level Light Therapy
Description: Administration of sham LLLT is designed to resemble active LLLT from the participant's perspective, but uses a dosage markedly below the minimal necessary threshold to elicit a response.
Study NCT00492557 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine
Description: Single 0.5 milliliter (mL) 13-valent pneumococcal conjugate vaccine (13vPnC) and a single 0.5 mL trivalent inactivated influenza vaccine (TIV), administered intramuscularly (IM), followed by a single 0.5 mL vaccine 13vPnC placebo, 1 month later.
Study NCT00492557 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13vPnC + TIV
Description: Single 0.5 mL 13vPnC placebo vaccine and a single 0.5 mL TIV, administered IM, followed by a single 0.5 mL 13vPnC vaccine, 1 month later.
Study NCT03081949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Sodium Selenite 200 µg/day for 3 months
Description: PPCM patients with selenium deficiency, who have not achieved LV reverse remodelling (LVRR) (LV end-diastolic dimension indexed to body surface area (LVEDDi) ≤33.0 mm/m2) at 6 months after diagnosis.
Study NCT02561949 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: YRI
Description: Youth Readiness Intervention (YRI) is an innovative, evidence-based mental health intervention to address co-morbid difficulties with externalizing problems (anger/emotion dysregulation) and internalizing problems (hopelessness/anxiety) among violence-affected youth. YRI methodology draws on evidence-based treatment elements commonly used in both cognitive-behavioral intervention and group interpersonal therapy. YRI has cross-cutting efficacy across a range of mental health conditions common in violence-affected youth. YRI will be delivered in 12 sessions over the course of 3 months.